Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV.

ABSTRACT:

Background

People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVDs) and geriatric syndromes, including frailty. REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) demonstrated a 36% reduction in major adverse cardiovascular events (MACE) with pitavastatin vs placebo but the role of statins for ASCVD prevention among frail PWH is not known.

Objectives

The purpose of this study was to evaluate whether frailty is associated with MACE and whether pitavastatin prevents MACE regardless of frailty.

Methods

We conducted a post hoc analysis of the REPRIEVE trial, a randomized, blinded trial of pitavastatin 4 mg vs placebo. Participants included PWH without ASCVD, aged 40 to 75 years. Frailty was measured with a 32-item frailty

SUBMITTER: Erlandson KM 

PROVIDER: S-EPMC12539451 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature